Mother root of *Aconitum carmichaelii Debeaux* exerts antinociceptive effect in Complet Freund’s Adjuvant-induced mice: roles of dynorphin/kappa-opioid system and transient receptor potential vanilloid type-1 ion channel

Chao Wang††, Danni Sun††, Chunfang Liu*, Chunyan Zhu1, Xianghong Jing2, Shuping Chen2, Cuiling Liu1, Kai Zhi1, Tengfei Xu3,4, Hui Wang1, Junling Liu2, Ying Xu1, Zhiqiang Liu3 and Na Lin*†

Abstract

**Background:** Processed Chuanwu (PCW), the mother root of *Aconitum carmichaelii Debeaux*, has been widely used as a classic Traditional Chinese Medicine for pain relief for over two millennia clinically. However, its action on chronic inflammatory pain has not been clarified. Here, we investigated the antinociceptive effect of PCW in complete Freund’s adjuvant (CFA)-induced mice and its possible mechanisms associated with opioid system and TRPV1 ion channel.

**Methods:** Male ICR mice were intraplantarly injected with CFA. PCW (0.34, 0.68 and 1.35 g/kg) was orally given to mice once a day for 7 days. Von frey hairs and planter test were assessed to evaluate the antinociceptive effect of PCW. To investigate the participation of dynorphin/opioid system in PCW antinociception, subtype-specific opioid receptor antagonists or anti-dynorphin A antiserum were used. To eliminate other central mechanisms that contribute to PCW antinociception, hot plate (50 °C) test were performed. Further, involvements of TRPV1 in PCW antinociception were evaluated in CFA-induced TRPV1−/− and TRPV1+/+ C57BL/6 male mice, and in capsaicin-induced nociception ICR naive mice pretreated with nor-BNI. Meanwhile, calcium imaging was performed in HEK293T-TRPV1 cells. Finally, rotarod, open-field tests and body temperature measurement were carried out to assess side effects of PCW.

**Results:** PCW dose-dependently attenuated mechanical and heat hypersensitivities with no tolerance, which could be partially attenuated by coadministration of k-opioid receptor antagonist nor-binaltorphimine (nor-BNI) or anti-dynorphin A (1–13) antiserum. And PCW antinociception was totally erased by pretreatment with nor-BNI in the hot plate test. In addition, PCW antinociception was decreased in TRPV1−/− mice compared to TRPV1+/+ group. And PCW still manifested inhibitory effects in capsaicin-induced nociception with nor-BNI pretreatment. PCW significantly inhibited capsaicin-induced calcium influx in HEK293T-TRPV1 cells. Finally, no detectable side effects were found in naive mice treated with PCW.
Conclusions: This study shows PCW's potent antinociceptive effect in inflammatory conditions without obvious side effects. This effect may result from the activation of κ-opioid receptor via dynorphin release and the inhibition of TRPV1. These findings indicate that PCW might be a potential agent for the management of chronic inflammatory pain.

Keywords: Processed mother root of Aconitum carmichaelii, CFA-induced inflammatory pain, Dynorphin/kappa-opioid system, TRPV1

Background

Inflammatory pain after tissue injury results in peripheral and central sensitization in peripheral tissues or spinal cord [1]. Indeed, hypersensitivities to thermal and mechanical stimuli are well documented characteristic symptom of chronic inflammatory pain [1, 2]. This chronic process causes patients to live with disability and continues to impart high health cost, economic loss to society. The mechanisms underlying the inflammatory pain remain to be elucidated. It is well-known that activation of opioid receptors result in the inhibition of chronic inflammatory pain [3]. On the other hand, transient receptor potential (TRP) ion channels in nociceptor peripheral terminals and dorsal root ganglia (DRG), especially TRPV1, contribute to the initiation and maintenance of hypersensitivity under inflammatory pain condition [4], and the deletion or inhibiting activity of TRPV1 leads to reduced inflammatory hyperalgesia [4–6]. Recently, several reports suggested that the activation of opioid receptors via inhibition of adenyl cyclase suppresses TRPV1 and other nonselective cation currents stimulated by inflammatory agents to induce antinociception [7–9]. Current analgesics aimed to modulate pain transduction and transmission in neurons has limited success [1]. There are two main classes of analgesic drugs: opioids and non-steroidal anti-inflammatory drugs (NSAIDs), whereas opioid analgesics are limited by tolerance, somnolence, respiratory depression, constipation and addiction [10, 11], NSAIDs are restricted by side effects such as gastrointestinal ulcers, bleeding, myocardial infarction and stroke [3, 12, 13]. And the induction of hyperthermia by TRPV1 antagonists has hampered the development of new drugs as analgesics [14]. Therefore, novel and efficient agents that are lack of central side effects and of adverse effects typical of NSAIDs are needed [3].

There is a growing interest in the utilization of medicinal plants for prevention and treatment of pain. The mother and lateral root of Aconitum carmichaelii Debus, called as “Chuanwu” (CW) and “Fuzi” in Chinese respectively, have been widely used to relieve pain and treat rheumatic arthritis and other inflammatory conditions for over 2000 years in clinic. Previous studies have shown that processed Fuzi, obtained after autoclaving crude Aconiti tuber (Ranunculaceae Aconitum carmichaeli Debeaux; Iwate, Japan) to minimize its toxicity, are efficient in relieving pain in repeated cold stress mice, chronic constriction injury (CCI) neuropathic pain as well as adjuvant articular inflammation in rats [15, 16]. And the analgesic effect of processed Fuzi is mediated by spinal κ- and μ-opioid receptors in CCI rats [17] and in tail-flick test [18–20]. On the other hand, it is found that CW has an anti-arithmetic effect in complete Freund’s adjuvant (CFA)-induced arthritis rats [21], and methanol extracts of crude Aconitum roots have anti-inflammatory effects in inhibiting acid-induced vascular permeability and carrageen-induced hind paw edema in mice [22]. However, the action of processed CW (PCW) on chronic inflammatory pain remains unclear. In the present study, we investigated the antinociceptive effect of PCW in CFA-induced cutaneous inflammation and its possible mechanisms associated with opioid system and TRPV1 ion channel were also explored.

Methods

This study was supported by the Research Ethics Committee of China Academy of Chinese Medical Sciences, Beijing, China (Permit Number: 2015–2028). All animals were treated in accordance with the guidelines and regulations for the use and care of animals at the Center for Laboratory Animal Care, China Academy of Chinese Medical Sciences and International Association for Suicide Prevention (IASP). All efforts were made to demonstrate consistent effects of the drug treatments and minimize the suffering of animals.

PCW preparation and UPLC–MS and UPLC–MS2 analysis

PCW was purchased from Beijing Huamiao Chinese medicine Engineering Development Center (Beijing, China) and authenticated by Professor Shilin Hu, China Academy of Chinese Medical Sciences. Hypeaconitine and mesaconitine were purchased from the Chinese Authenticating Institute of Material and Biological Products (Beijing, China). Benzoylmesaconine, benzoylhypaconitine, aconitine, and benzoylaconitine were purchased from Lan Yuan Biological technology Co., Ltd. (Shanghai, China). Reserpine as the internal standard was purchased from Sigma (USA).
For PCW preparation, we used the method as we previously described [23, 24]. Briefly, PCW was dried, homogenized to fine powders by a plant pulverizer and screened by a 0.45 mm sieve. Then 50 g powdered PCW were immersed in 500 ml deionized water for 1 h, and heated to refluxing for 1.5 h. Water as 8 times of the total weight was added for another 1.5 h refluxing after filtered. The filtered extraction solutions were concentrated to 50 ml, and kept at −20 °C and was diluted with deionized water to proper concentration for in vivo study. PCW extraction procedures were carried out according to our previous study [24].

**UPLC-MS and UPLC-MS2 analysis**

Chromatographic separation was performed on a Waters CORTECS UPLC BEH C18 Column (2.7 μm, 1.66 × 100 mm) keeping at 35 °C. 0.1 % aqueous formic acid (v/v) (A) and acetonitrile (B) were used as the mobile phase. The gradient elution with the flow rate of 0.3 mL/min was performed as follows: 10 % B at 0–2 min, 10–15 % B at 2–7 min, 15–30 % B at 7–15 min, 30–39 % B at 15–21 min, 39 % up to 100 % at 21–25 min. The sample inject volume was 5 μL. The MS analysis was carried out by the ESI source in both positive and negative ion mode, and full-scan mass range was 100–1,200 Da. The source temperature was 110 °C, and the desolvation gas temperature was 300 °C. The flow rates of cone and desolvation gas were set at 30 L/h and 600 L/h, respectively. The voltages of capillary, cone and extraction cone in positive ion mode were set at 2.5 kV, 35 V and 5.0 V, respectively, and in negative ion mode, they were set at 2.0 kV, 35 V and 5.0 V, respectively.

**Data processing**

Data were acquired with MassLynx 4.1 and processed for calibration and for quantification of the analytes with Target Lynx software (Micromass UK).

Special conditions of MS/MS of each analyte are important for the development of a satisfactory quantification method by LC-MS/MS. Therefore, the unintellistart function was used to find the most specific and sensitive detection parameters of each analyte in MRM mode. Ion transitions and instrumental parameters in MRM mode are shown in Table 1. Typical multiple reaction monitoring chromatograms of the compounds in positive ion mode are shown in Fig. 1.

The regression equations obtained by least squared regression using weighting factor (1/x2). Correlation coefficients (r2) were ≥0.9 for all calibration curves, and observed deviations were within ±15 % for all calibration concentrations. The calibration curves, calibration ranges and contented in PCW of these compounds are performed in Table 2.

**Animals**

Male mice of 8–12 weeks old were used in all experiments. C57BL/6 TRPV1-knockout (KO) mice (TRPV1−/−) were purchased from Jackson Lab (USA). ICR mice and C57BL/6 wild-type (WT) mice were purchased from Laboratory Animal Center of Academy of Military Medical Sciences, Beijing, China (License No. SCXK-2012-004). They were kept in a temperature controlled environment (22 ± 1 °C), 55 ± 5 % relative humidity with a 12h:12 h light–dark cycle and fed with standard chow, for at least 1 week before any manipulations. Animals were habituated to the laboratory conditions for at least 1 h before testing and all experiments were performed during the light phase of the cycle. All the experiments were performed by two independent, blinded observers.

**CFA-induced chronic inflammatory pain**

ICR mice were randomly divided into six groups (n = 8): the control group (Control), the CFA (Sigma-Aldrich, St.Louis, MO, USA)-induced inflammatory group (CFA), CFA-induced mice treated with PCW groups (CFA + PCW 0.34, 0.68, and 1.35 g/kg, respectively), and control mice treated with PCW group (PCW 1.35 g/kg). CFA or control groups received an intraplantar injection of 20 μl of CFA or vehicle (2 % tween 80 plus saline) to

| Table 1 | Ion transitions and instrumental parameters for their LC–MS/MS quantification in MRM mode |
|---------|----------------------------------------------------------------------------------------------------------------------------------|
| Sample  | Ion mode | MRM | CV | CE | LOQ | LOD |
| Benzoylmesaconine | + | 590.33 > 77.02 | 52 | 78 | 2.1 | 0.73 |
| Aconitine | + | 646.39 > 586.34 | 50 | 34 | 1.9 | 0.6 |
| Mesantine | + | 632.33 > 105.04 | 42 | 56 | 2.2 | 0.9 |
| Benzoylhypacoitine | + | 574.32 > 542.35 | 46 | 34 | 1.8 | 0.6 |
| Benzoylaconitine | + | 604.41 > 105.04 | 58 | 54 | 4.3 | 1.7 |
| Hypaconitine | + | 616.36 > 556.31 | 42 | 32 | 1.9 | 0.61 |
| Reserpine(is) | + | 609.33 > 174.07 | 40 | 42 | – | – |

IS internal standard, CE collision energy (eV), CV cone voltage (V), MRM specific mass transition, LOQ limit of quantification (ng/ml), LOD limit of detection (ng/ml)
48 h later, mice were orally administered by syringe feeding with distilled water (10 ml/kg) or PCW daily for 7 days and mechanical and thermal hypersensitivities were evaluated accordingly.

**Measurement of mechanical hypersensitivity**

Mice were acclimatized in individual clear boxes on wire-mesh platform, mechanical hypersensitivity was assessed by the sensitivity to the application of von Frey hairs (Stoelting Co., Chicago, USA). The von Frey filaments of 0.04–2.0 g were used and held perpendicularly to the plantar surface of the injected paw for 2–4 s. An abrupt withdrawal of injured paw or flinching behaviour immediately following removal of von Frey hairs indicate positive responses. A 50 % paw withdrawal threshold (PWT) was calculated following Dixon’s up-down method [25]. The PWT was analyzed at 0, 0.5, 1, 1.5, 2, 3, 4, 24 h and 3rd, 5th, 7th days post PCW administration, respectively.

**Measurement of the heat hypersensitivity in plantar test**

The plantar test was assessed for thermal hypersensitivity as previously described [26]. Briefly, mice were acclimatized to an apparatus (Ugo Basile Srl, Comerio VA, Italy) consisting of individual Perspex boxes, an infrared radiant heat source was directed to middle part of the plantar surface of the hind paw. We adjusted the basal paw withdrawal latency (PWL) to 9–12 s and set a cut-off time of 20 s to prevent tissue damage. PWL were measured at time point of 1 h on the 2nd, 4th, 6th day post PCW (0.34–1.35 g/kg, p.o.) or vehicle administration, using the same mouse that for mechanical hypersensitivity assessment, and three trials for each hind paw. The interval of PWL measurement was 5 min.

**Investigation the mechanisms of antinociception of PCW in mice**

**Involvement of opiod system**

To determine the potential role of opioid system in the antinociceptive effects of PCW, CFA-induced mice were pretreated with cypromide (2.3 μmol/kg, i.p., a selective μ-opioid receptor antagonist, Sigma) or nor-binaltorphimine (nor-BNI, 13.6 μmol/kg, s.c., a preferential κ-opioid receptor antagonist, Sigma) or naltrindole (11.1 μmol/kg, i.p., a selective δ-opioid receptor

**Table 2** Calibration curves, concentration ranges and contented of 6 main components in PCW

| Sample               | Calibration curves                        | Concentration ranges (μg/ml) | Contented in PCW (μg/g) |
|----------------------|------------------------------------------|------------------------------|-------------------------|
| Benzoylmesaconine    | \(y = 0.6530x + 0.0857 \) \((r^2 = 0.9991)\) | 0.09–90                     | 0.218                   |
| Aconitine            | \(y = 0.5990x + 0.0736 \) \((r^2 = 0.9975)\) | 0.09–90                     | –                       |
| Benzoylhypacoitine   | \(y = 0.3158x + 0.0488 \) \((r^2 = 0.9928)\) | 0.09–90                     | 0.051                   |
| Benzoylaconitine     | \(y = 0.9983x + 0.0823 \) \((r^2 = 0.9966)\) | 0.09–90                     | 0.036                   |
| Hypaconitine         | \(y = 0.5151x + 0.0896 \) \((r^2 = 0.9778)\) | 0.09–90                     | 0.011                   |
| Mesactonine          | \(y = 0.4919x + 0.0520 \) \((r^2 = 0.9903)\) | 0.09–90                     | 0.006                   |
antagonist, Sigma). 15 min later, animals received an administration of PCW (1.35 g/kg, p.o.) or distilled water (10 ml/kg, p.o.), and PWT of injured paw was evaluated 1 h later. In another set of experiments, mice co-treated with PCW and nor-BNI were subjected to the plantar test for heat hypersensitivity as described above.

Since endogenous dynorphin plays an important role in nociception modulation in inflammatory conditions [27], we evaluate the role of endogenous dynorphin in PCW antinociception by intraspinal injection (i.t.) of anti-dynorphin A (1–13) antiserum (Bachem/Peninsula Laboratories, Belmont, CA, USA) in CFA-induced mice. 72 h after CFA treatment, mice were received a dose of anti-dynorphin A (1–13) antiserum (5 μg/5 μl, i.t.), then, PCW (1.35 g/kg, p.o.) was immediately administrated, and mechanical or heat hypersensitivities were measured 1 h later. The anti-dynorphin A (1–13) antiserum was dissolved in saline and was injected by a 29-gauge needle between the L5 and L6 intervertebral spaces within 5 min [28].

To explore whether other possible central mechanisms contribute to PCW antinociceptive effect, heat hypersensitivity to hot plate was evaluated as previously described [29]. Briefly, CFA-induced mice were pretreated with nor-BNI (13.6 μmol/kg, s.c.). 15 min later, animals received an administration of PCW (1.35 g/kg, p.o.) or distilled water (10 ml/kg, p.o.), then mice were placed in a hot plate set at 50 ± 1 °C (Cold-hot Plate, Ugo Basile, Comerio, Italy) and the nociception was recorded as the latency time to withdrawal, shaking or licking the injured paw 1 h later. A cut-off time of 20 s was set to avoid tissue damage.

Involvement of TRPV1 ion channel
To evaluate the possible involvement of TRPV1 ion channel on PCW antinociceptive effect, TRPV1+/+ and TRPV1−/− mice were used. First, baseline sensory thresholds in TRPV1+/+ and TRPV1−/− mice were tested, then mice received an intraplantar injection of 20 μl of CFA to the right hind paw. 48 h later, mice were orally administered by syringe feeding with PCW (1.35 g/kg) or distilled water once. PWT of the injured paw was assessed before and 0.5, 1, 2, 3, 4 h post-PCW or distilled water administration, respectively.

To further explore the possible involvement of TRPV1 in PCW antinociception, capsaicin-induced spontaneous nociception, mechanical and thermal hypersensitivities were assessed pretreated with κ-opioid receptor antagonist, as previously described [30, 31]. Mice were pretreated with AMG9810 (a selective TRPV1 antagonist, 30 mg/kg, i.p., Tocris Bioscience, Ellisville, Missouri, USA) or Nor-BNI (13.6 μmol/kg, s.c., 15 min before PCW administration), PCW (1.35 g/kg, p.o.) or distilled water (10 ml/kg, p.o.) 1 h (for p.o. administration) or 0.5 h (for i.p. administration) prior to the injection of 20 μl capsaicin (2 μg/paw, Tocris Bioscience) or vehicle to the plantar surface of the right hind paw, respectively. Immediately after capsaicin application, mice were placed into clear observation boxes and the nociceptive response was evaluated as the time of spent licking the injected paw during 5 min. In another set of experiments, the same mice were immediately put into the individual clear boxes on wire-mesh platform for PWT assessment 15 min after capsaicin administration. In the third experiment, mice received the same administrations of AMG9810, Nor-BNI, PCW or distilled water, as described above, and then mice were acclimatized in individual clear boxes for 1 h. Immediately after vehicle or capsaicin intraplantar injection, mice were again put into the individual clear boxes, heat hypersensitivity of the injured paw was assessed in planter test, 15 min after capsaicin treatment.

Side effects assessments
Rotarod and open-field test
The effects of PCW on locomotor activity was assessed as previously reported [32]. Briefly, mice were trained on the rotarod (8 rpm) until they could remain on the apparatus for 1 min without falling. Then, mice were subjected to rotarod test 1 h after PCW (1.35 g/kg, p.o.) or vehicle (10 ml/kg) administration. The number of falls and latency to first fall from the apparatus were recorded for duration of 4 min. To exclude possible nonspecific muscle relaxant or sedative effects, mice were subjected to the open-field test [32]. The floor of the arena was divided into 12 equal squares, and the number of squares crossed with all paws was counted in a 5-min session.

Body temperature
The difference between the values before and after PCW (1.35 g/kg, p.o.) administration were calculated (Δ °C) as described previously [32]. The TRPV1 antagonist (AMG9810) (30 μmol/kg, p.o.) was used as a positive control.

Cell viability assay
Human embryonic kidney (HEK293) cells were seeded in 96-well plates and incubated in serum free sterile DMEM supplemented with 100 U/mL penicillin, 100 μg/mL streptomycin, and 2 mM Glu-glutamine for 24 h. Cells were then incubated with medium containing (0.25, 0.5, 1 μg/ml, respectively) for 24 h. After treatment, cells were washed twice with phosphate-buffered saline (PBS, pH 7.4), and then cell viability was determined by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method using Cell Titer
Non-Radioactive Cell Proliferation Assay (Promega, Madison, USA) according to the manufacturer’s instructions. All absorbances at 570 nm were measured with a Tecan Infinite M200 Pro microplate reader (Tecan, Mannedorf, Switzerland). The experiments were carried out 2 times in triplicate measurements.

Calcium imaging

Cloning and cell culture

TRPV1 sequence was amplified from homo genome and cloned into pMig plasmid (Addgene, #9044). HEK293T cells were cultured in DMEM with 10 % fetal calf serum, 100 U/l penicillin and 100 μg/ml streptomycin at 37 °C, 5 % CO₂. Cells seeded on poly-l-lysine-covered coverslips at the density of 1 × 10⁶/6-well plate (four coverslips/one well of 6-well plate) were transfected with 4 μg pMig-TRPV1 by lipofectamine® 2000 (Invitrogen, Mount Waverley, Australia) and used for functional calcium imaging within 24–48 h after transfection.

Detection of intracellular Ca²⁺

Cells plated on coverslips in 6-well plated were transfected and cultured in calcium-containing DMEM overnight and then treated with PCW (0.25, 0.5, 1 μg/ml, respectively) for 30 min. Fluo-4AM (40 μM) was loaded into HEK293T-TRPV1 cells for 30 min at 37 °C and then 30 min at room temperature. Cells were then treated with capsaicin (8 μM). Fluorescence changes were examined by a Zeiss Lsm710 confocal microscope (Carl Zeiss AG, Oberkochen, Germany). The experiments were repeated independently for two times in triplicate measurements.

Statistical analysis

Data are presented as mean ± SEM. Data obtained from mechanical and thermal hypersensitivity experiments were analyzed by two-way ANOVA followed by Bonferroni post hoc test. Other data were analyzed by one-way analysis of variance (ANOVA) followed by Student–Newman–Keuls post hoc test. A value of P < 0.05 was taken to be significant.

Results

PCW attenuated mechanical and heat hypersensitivities in CFA-induced mice

To investigate the antinociceptive effects of PCW, a chronic inflammatory model of nociception was used. Mechanical hypersensitivity was evaluated from day 1 to day 7 48 h after an intraplantar injection of CFA in mice. As showed in Fig. 2, CFA caused significant mechanical hypersensitivity characterized by the reduced PWT compared with control group. Oral administration of PCW (0.34, 0.68, and 1.35 g/kg) was able to significantly reverse mechanical hypersensitivity and this effect lasted up to 3 h in high dose group. The maximum effect was observed 1 h post PCW treatment. And this antinociceptive effect was maintained while PCW (0.34, 0.68, and 1.35 g/kg) was orally administered daily, until the 7th day post-treatment. Notably, on the 7th day, PCW reduced mechanical hypersensitivity with a time-course effect profile similar to that of the first day, ruling out the possibility of drug tolerance. Although PCW (1.35 g/kg) potently reduced mechanical hypersensitivity in CFA-induced nociception, it did not alter the baseline thresholds in normal control mice, suggesting that PCW
Hypersensitivity to heat stimulus was explored in CFA-induced mice in a plantar test. As showed in Fig. 3, oral administration of PCW significantly reversed heat hypersensitivity in a dose-dependent manner. And similar inhibitions were observed in each dose of PCW on the 2nd, 4th and 6th days after treatment. These results also suggested that the antinociceptive effects of PCW were not susceptible to tolerance. Consistent with mechanical results above, PCW (1.35 g/kg) did not produce any analgesic effect per se in a plantar test even with repeated administration of 7 consecutive days.

**Involvement of kappa-opioid/dynorphin system in PCW antinociception in CFA-induced mice**

Previous reported that activations of μ-, δ-, and κ-opioid receptors lead to significant reduced inflammatory hypersensitivities [33–36]. To assess the antinociceptive mechanism of PCW on opioid system, specific antagonists of opioid receptors were used. As showed in Fig. 4a, PWT was strikingly reduced 48 h post CFA treatment. PCW (1.35 g/kg) significantly reversed PWT with inhibition of 59 ± 5%, and applications of μ- or δ-opioid receptor antagonist cyprodime or naltrindole did not alter the antinociceptive effect of PCW with similar inhibitions of 59 ± 7 and 61 ± 7%, respectively. Interestingly, when nor-BNI, a selective antagonist of κ-opioid receptor, was used, the antinociceptive effects of PCW significantly reduced, with an inhibition of 32 ± 6 %. Heat hypersensitivity in a plantar test was also examined. As demonstrated in Fig. 4b, CFA caused a significant reduced in heat hypersensitivity, and this effect were reversed by treatment of PCW with inhibition of 66 ± 4 %, while nor-BNI could significantly reverse its antinociception with an inhibition of 15 ± 6 %. These results indicated that the activation of κ-opioid receptor, but not μ- or δ-opioid receptor, contribute to the antinociceptive effect of PCW.

Endogenous dynorphin that binds to and activates κ-opioid receptor plays important role in pain modulation under inflammatory conditions [27]. We further investigated whether PCW exerted its antinociceptive effects via dynorphin release in the spinal cord. As demonstrated in Fig. 4c, d, PCW significantly increased PWT and PWL compared to CFA group, and these effects could be significantly decreased by coadministration of anti-dynorphin A (1–13) antiserum (i.t.), with similar inhibition as in the nor-BNI-treated mice described above.

To explore whether other possible central mechanisms contribute to the antinociceptive effects of PCW, heat hypersensitivity in a hot plate test was further investigated. As showed in Fig. 4e, CFA obviously reduced latency time to paw withdrawal compared to control group, and PCW (1.35 g/kg, p.o.) could reverse the latency time, while this effect was totally blocked by nor-BNI pretreatment, even in a higher dose of PCW (3.00 g/kg, p.o.) (data not shown). These results supported the central analgesic mechanism of PCW that the activation of κ-opioid receptor contributes to its antinociceptive process, and it also suggested that other central mechanisms may not be involved in the antinociceptive effects of PCW under inflammatory conditions.

**Involvement of TRPV1 in PCW antinociception**

TRPV1 ion channel plays an important role in the initiation and maintenance of mechanical and heat hypersensitivities in inflammatory conditions [4–6]. We investigated whether TRPV1 was involved in the antinociceptive effect of PCW. As demonstrated in Fig. 5a, 48 h after CFA injection, both TRPV1+/+ and TRPV1−/− mice exhibited decreased PWT.

---

**Fig. 3** Effect of PCW on CFA-induced heat hypersensitivity in mice. Evaluations of heat hypersensitivity were done 1 h post-treatment in a plantar test on the 2nd (a), 4th (b) and 6th (c) days using the same mice for mechanical hypersensitivity assessment. Data are represented as the mean ± SEM (n = 8). And ###P < 0.001 vs. the control group; *P < 0.05, **P < 0.01 and ***P < 0.001 vs. the CFA group, respectively.
By contrast, CFA reduced the PWL in wild-type mice, but not in TRPV1−/− group (Fig. 5b). Therefore, PWT were chosen for the assessments of TRPV1 ion channel in the antinociceptive effects of PCW. As showed in Fig. 5c, PCW caused a rebound of mechanical sensitivity toward baselines both in TRPV1+/+ and TRPV1−/− mice 0.5, 1 and 2 h post treatment, and the inhibitions in TRPV1+/+ mice were about 23% higher than that in TRPV1−/− group at 0.5 and
1 h post PCW treatment. These data suggested that TRPV1 relate to the antinociceptive effect of PCW.

To get the knowledge on the antinociceptive effects of PCW through TRPV1 ion channel, capsaicin-induced nociception was further examined. As shown in Fig. 6a, capsaicin, a specific activator of TRPV1, induced obvious spontaneous nociception, and this nociception was significantly reduced in AMG9810 and PCW-treated groups with similar inhibitions of 52 ± 3 and 54 ± 4 %, respectively. While pretreated with nor-BNI, PCW produced an inhibition of 21 ± 2 %. Capsaicin also induced obvious mechanical and thermal hypersensitivities, which were reduced by AMG9810 and PCW with similar inhibitions, and PCW could reverse these hypersensitivities with pretreatment of nor-BNI with inhibitions of 24 ± 5 and 27 ± 6 %, respectively (Fig. 6b, c). These results further supported the antinociceptive effects of PCW in a capsaicin-induced nociception test, and this antinociception was also independent of the activation of κ-opioid receptor.

To further explore the effect of PCW on TRPV1 activity, the intracellular calcium levels were measured in HEK293T-TRPV1 cells. As demonstrated in Fig. 7a–c, capsaicin significantly increased intracellular calcium in HEK293T-TRPV1 cells, while PCW (0.25–1 µg/ml) dose-dependently decreased capsaicin-induced calcium influx. These results suggested that PCW has direct inhibitory effect on TRPV1 activity. Next, we examined whether the above effect was due to its cytotoxicity. Our results showed that PCW (0.25–1 µg/ml) did not exert any cytotoxic effects on HEK293T cells under the experimental conditions used in the present study (Fig. 7d), suggesting that PCW might specifically inhibit TRPV1 activity in vitro.

**PCW did not induce detectable adverse effects**

Since PCW may stimulate κ-opioid receptor via dynorphin release to produce antinociception, we investigated whether this medicine produced common side effects of opioid-like drugs in rodents on motor performance. The active dose of PCW (1.35 g/kg, p.o.) did not alter forced or spontaneous locomotion, as assessed by the rotarod and open-field tests, respectively (Table 3). Meanwhile, PCW may inhibit TRPV1 activity to produce antinociception. Thus, we further explored whether PCW caused body temperature alteration as TRPV1 antagonists [14]. As demonstrated in Table 3, PCW (1.35 g/kg p.o.) did not induced hyperthermia compared to vehicle group, while the TRPV1 antagonist AMG9810 induced a significant increase in rectal temperature. In addition, PCW treatment for 7 days did not induce significant body weight change and ulceration of the gastric mucosa compared with CFA and normal control groups (data not shown).

**Discussion**

PCW is known to be used effectively to treat joint pain and inflammatory diseases in clinic. However, its antinociceptive properties and the possible mechanisms remain unclear. Data presented in this study indicate PCW could potently attenuate hypersensitivities to mechanical and heat stimuli without tolerance in CFA-induced nociception. Moreover, the antinociception of PCW was partially reversed by coadministration with nor-BNI and anti-dynorphin A antiserum, respectively. And this antinociceptive effect was also reduced in TRPV1−/− mice. In addition, PCW could effectively inhibit capsaicin-induced nociceptive behaviors with coadministration of nor-BNI. PCW also reduced capsaicin-induced calcium influx in HEK293T-TRPV1 cells. Thus, our data showed the potent antinociceptive effects of PCW and pointed
to its connection with dynorphin/κ-opioid system and TRPV1 in inflammatory conditions.

CFA-induced cutaneous inflammation in rodents effectively mimics a chronic inflammatory pain condition. A characteristic symptom of this model is that it displays hyperalgesia to mechanical and thermal stimulation [1, 2], and has been widely used to study persistent inflammatory pain. In this study, we analyzed the antinociceptive effects of PCW in CFA-induced cutaneous inflammation. Our results showed that oral
administration of PCW at doses of 0.34–1.35 g/kg could remarkably reduce inflammatory mechanical and heat hypersensitivities without tolerance, which confirmed its antinociceptive action in clinical use for pain relief.

Recent studies reported that opioid drugs lead to more-pronounced antinociceptive effects on inflammatory pain [33–36]. Previous reports suggested that μ- and δ-opioid receptors are involved in the antinociceptive effects of processed Fuzi (the lateral root of Aconitum carmichaelii Debx.) [17–20]. These studies encourage us to screen the specific opioid receptors that relate to PCW antinociception by using selective opioid receptors antagonists. Our results showed that pretreatment with nor-binaltorphimine, a preferential κ-opioid receptor antagonist, could markedly eliminate the antinociception of PCW, while treatments of cyprodime, a selective μ-opioid receptor antagonist and naltrindole, a selective δ-opioid receptor antagonist did not reduce the analgesic effects of PCW, indicating that κ-opioid receptor, but not μ-, or δ-opioid receptor contributes to the antinociceptive effect of PCW. It has been reported that endogenous dynorphin synthesis increased in the lumber spinal cord and plays an important role in nociception modulation under inflammatory conditions [27]. In the present study, the enhanced antinociceptive effect of PCW under inflammatory conditions may result from the increased release of endogenous dynorphin from both PCW application and CFA-induced nociception in the spinal cord and the subsequent activation of kappa opioid receptor. And this hypothesis was supported by our findings that the antinociceptive effects of PCW significantly decreased by anti-dynorphin A (1–13) antiserum coadministration (i.t.). Although the antinociception of PCW in CFA-induced inflammation still remained with coadministration of nor-BNI or anti-dynorphin A (1–13) antiserum, PCW did not produce any antinociception with coadministration of nor-BNI in the hot plate test, suggesting that the antinociceptive effects of PCW may also relate to certain peripheral mechanisms.

TRPV1 is a heat transducer in normal and pathological conditions, activated by temperatures above 42 °C, and deleting or inhibiting the activity of this heat-sensitive channel results in reducing inflammatory heat and mechanical hyperalgesia [4–6]. Considering the close connections of this ion channel with mechanical and heat hypersensitivities in inflammatory pain conditions, it is reasonable to think that the antinociceptive effect of PCW may be mediated by TRPV1. To test this hypothesis, we firstly investigated the antinociceptive effects of PCW in TRPV1 wild-type and TRPV1−/− mice. Our results showed that the antinociception of PCW was reduced in TRPV1−/− mice compared to TRPV1+/+ group in inflammatory conditions, indicating TRPV1 was involved in antinociceptive process of PCW. Next, PCW antinociception was also explored in capsaicin tests in vivo and in vitro. Our data showed that PCW could significantly reduce capsaicin-induced nociceptive response, mechanical and heat hypersensitivities in mice. Since activation of the opioid receptors reduces TRPs-mediated cellular and/or behavioural responses [37–40], the antinociceptive effects of PCW were further examined on capsaicin-induced nociception with pretreatment of nor-binaltorphimine. Our findings demonstrated that PCW still manifested inhibitory effects on capsaicin-induced nociception with nor-BIN pretreatment, which further pointed to the connection of TRPV1 in PCW antinociception. Additionally, calcium image analysis confirmed the direct inhibitory action of PCW on TRPV1 ion channel. Taken together, these findings indicated that PCW may effectively inhibit TRPV1 activity, which were consistent with our recent report that Wu-Tou decoction, with the main component of PCW, could inhibit capsaicin-induced nociception in mice [41].

Throughout the present study, the antinociceptive effect of PCW was not susceptible to tolerance and the active dose of PCW 1.35 g/kg did not cause motor impairment, hyperthermia. Furthermore, the prolonged treatment of PCW (0.34–1.35 g/kg) did not cause significant change in body weight and gastrointestinal ulcers of mice. Therefore, it is likely that PCW selectively exerts its antinociceptive effect in inflammatory conditions. Current analgesics aim to modulate pain transduction and transmission in neurons has limited success in pain relieve [1], and targeting both the neuronal and nonneuronal mechanisms and excessive neuroinflammation have attracted considerable attention for better chronic pain treatments [1, 42]. Considering the main mechanisms of neuroinflammation and new notions of multi-targets intervention for chronic pain [1, 42], it is reasonable to

### Table 3 The effects of PCW on locomotion and body temperature of mice 1 h after administration

| Treatment | Rotarod test | Open-field test | Body temperature |
|-----------|--------------|-----------------|------------------|
|           | First fall (s) | Falls | Crossing | Rearing | Temperature |
| Vehicle | 176 ± 21 | 23 ± 0.5 | 47 ± 8 | 11 ± 1 | 0.29 ± 0.06 |
| PCW | 183 ± 18 | 1.7 ± 0.3 | 54 ± 6 | 9 ± 1 | 0.36 ± 0.06 |
| AMG9810 | – | – | – | – | 1.09 ± 0.12*** |

Mice were randomly divided into 3 groups: the Vehicle (10 ml/kg, p.o.) group, PCW (1.35 g/kg, p.o.) group and AMG9810 (30 μmol/kg, p.o.)-treated group for rotarod test, open-field test or body temperature assessment. Significant differences were not observed in the locomotion or body temperature tests between vehicle and PCW (1.34 g/kg, p.o.) groups, while AMG9810 (30 μmol/kg, p.o.) significantly increased rectal temperature compared to vehicle or PCW (1.34 g/kg, p.o.) groups. Data are expressed as mean ± SEM. (n = 6)

*** P < 0.001 vs. the vehicle or PCW groups
believe that PCW might have better features than other known anagisics.

Conclusions
Our data offered convincing evidence that PCW has potent antinociceptive effect in chronic inflammation conditions by attenuating mechanical and heat hyper-sensitivity without obvious side effect. These effects may result from the stimulation of κ-opioid receptor by increased dynorphin release in the lumbar spinal cord and the inhibition of TRPV1 ion channel. Collectively, these findings confirm and add new information about antinociceptive properties of PCW, it also indicates that PCW might be a potential agent for the management of chronic inflammatory pain.

Abbreviations
PCW: processed Chuanwu; NSAIDs: non-steroidal anti-inflammatory drugs; CFA: complete Freund’s Adjuvant; nor-BNI: nor-binaltorphimine; κ: kappa; TRPV1: transient receptor potential vanilloid type-1 ion channel; TRP: transient receptor potential; DRG: dorsal root ganglia; HBQ93 cells: Human embryonic kidney cells; CCI: chronic constriction injury; i.t.: intraspinal injection; WT: wild-type; PWT: paw withdrawal threshold; PWL: paw withdrawal latency; MTT: 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.

Authors’ contributions
CW and DNS carried out all the animal experiments. CYZ, CLL and KZ carried out the cell experiments. XHJ, SPC and JLL participated the experiments of chemical analysis. CW and CFL carried out the chemical analysis. TFX and YX carried out the cell experiments. XHJ, SPC and JLL participated in the design of the study, performed the statistical analysis and drafted the manuscript. All authors read and approved the final manuscript.

Author details
1 Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, No. 16, Nanxiaoqiao, Dongzhimennei, Beijing 100700, China. 2 Institute Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China. 3 National Center for Mass Spectrometry in Changchun and Jilin province Key Laboratory for Traditional Chinese Medicine Chemistry and Mass Spectrometry and Chemical Biology Laboratory, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China. 4 University of Chinese Academy of Sciences, Beijing 100049, China.

Acknowledgements
This work was supported by grants from the National Natural Science Foundation of China (No. 81173628, 81374068) and the National Basic Research Program of China (973 Program) (No. 2011CB505300, 2011CB505305).

Compliance with ethical guidelines
Competing interests
The authors declare that they have no competing interest.

Received: 30 April 2015 Accepted: 12 August 2015

Published online: 30 August 2015

References
1. Ji RR, Xu ZZ, Gao YJ. Emerging targets in neuroinflammation-driven chronic pain. Nat Rev Drug Discov. 2014;13(7):533–48.
2. Levine JD, Alessandri-Haber N. TRP channels: targets for the relief of pain. Biochim Biophys Acta. 2007;1772(8):989–1003.
3. Stein C, Baerwald C. Opioids for the treatment of arthritic pain. Expert Opin Pharmacother. 2014;15(2):193–202.
4. Sousa-Valente J, Andreou AP, Urban L, Nagy I. Transient receptor potential ion channels in primary sensory neurons as targets for novel analgesics. Br J Pharmacol. 2014;171(10):2508–27.
5. Schumacher MA. Transient receptor potential channels in pain and inflammation: therapeutic opportunities. Pain Pract. 2010;10(3):185–200.
6. Brederson JD, Kym PR, Szalasi A. Targeting TRP channels for pain relief. Eur J Pharmacol. 2013;716(1–3):61–76.
7. Walwyn W, Evans CJ, Hales TG. Beta-arrestin2 and c-Src regulate the constitutive activity and recycling of mu opioid receptors in dorsal root ganglion neurons. J Neurosci. 2007;27(19):5092–104.
8. Moshouab R, Stein C. Fentanyl decreases discharges of C and A nociceptors to supra threshold mechanical stimulation in chronic inflammation. J Neurophysiol. 2012;108(10):2827–36.
9. Spanh V, Fischer O, Endres-Becker J, Schäfer M, Stein C, Zöllner C. Opioid withdrawal increases transient receptor potential vanilloid 1 activity in a protein kinase A-dependent manner. Pain. 2013;154(4):598–608.
10. Woolf CJ. Mu and delta opioid receptors diverge. Cell. 2009;137(6):978–8.
11. Poreca F, Ossipov MH. Nausea and vomiting side effects with opioid analgesics during treatment of chronic pain: mechanisms, implications and management options. Pain Med. 2009;10(4):654–62.
12. Huscher D, Theile K, Gromnicz-Ihle E, Hein G, Demary W; Dreher R, Zink A, Burtges F. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009;68(7):1119–24.
13. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, Egger M, Juni P. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086.
14. Gavva NR. Body-temperature maintenance as the predominant function of the vanilloid receptor TRPV1. Trends Pharmacol Sci. 2008;29(1):550–7.
15. Xu H, Arita H, Hayashida M, Zhang L, Sekiyama H, Hanaoka K. Pain-relieving effects of processed Aconiti tuber in CCI-neuropathic rats. J Ethnopharmacol. 2006;103(3):392–7.
16. Oyama T, Isono T, Suzuki Y, Hayakawa Y. Anti-nociceptive effects of aconiti tuber and its alkaloids. Am J Chin Med. 1994;22(2):175–82.
17. Wu G, Huang W, Zhang H, Li Q, Zhou J, Shu H. Inhibitory effects of processed Aconiti tuber on morphine-induced conditioned place preference in rats. J Ethnopharmacol. 2011;136(1):254–9.
18. Shu H, Hayashida M, Chiba S, Sekiyama H, Kitamura T, Yamada Y, Hanaoka K, Arita H. Inhibitory effect of processed Aconiti tuber on the development of antinociceptive tolerance to morphine: evaluation with a thermal assay. J Ethnopharmacol. 2007;113(3):560–3.
19. Omiya Y, Goto K, Suzuki Y, Ishige A, Komatsu Y. Analgesia-producing mechanism of processed Aconiti tuber: role of dynorphin, an endog-enous kappa-opioid ligand, in the rodent spinal cord. Jpn J Pharmacol. 1999;79(3):295–301.
20. Liou SS, Liu IM, Lai MC, Cheng JT. Comparison of the antinociceptive action of crude Fuzei, the root of Aconitum, and its processed products. J Ethnopharmacol. 2000;99(3):79–83.
21. Xue L, Zhang HY, Qin L, Wang XC, Wang L. Effect of chuanwu and baishao used separately or in combination on adjuvant arthritis in rats. Zhongguo Zhong Yao Za Zhi. 2000;25(3):175–8.
22. Hickino H, Konno C, Takata H, Yamada Y, Yamada C, Ohizumi Y, Sugio K, Fujimura H. Antinflammatory principles of Aconits root. J Pharmacobiodyn. 1980;3(10):514–25.
23. Qi Y, Li S, Pi Z, Song F, Lin N, Liu S, Liu Z. Chemical profiling of Wu-tou decoction by UPLC-Q-TOF-MS. Talanta. 2014;118:21–9.
24. Zhi H, Wang C, Qi Y, Song F, Liu Z, Liu S. Fingerprint analysis of Radix Aconiti using ultra-performance liquid chromatography-electrospray ionization/tandem mass spectrometry (UPLC-ESI/MSn) combined with stoichiometry Talanta. 2013;109:56–65.
25. Chapman SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods. 1994;53(1):55–63.
26. Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain. 1988;32(1):77–88.
27. Millan MJ, Czlonkowski A, Pilcher CW, Almeida OF, Millan MH, Colpaert FC, Herz A. A model of chronic pain in the rat functional correlates of alterations in the activity of opioid systems. J Neurosci. 1987;7(1):77–87.
28. Hylden JL, Wilcox GL. Intrathecal morphine in mice: a new technique. Eur J Pharmacol. 1980:67(2–3):313–6.
29. Luszczki JJ, Czuczwar SJ. Isobolographic characterization of interactions between vigabatrin and tiagabine in two experimental models of epilepsy. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):529–38.
30. Brandão MS, Pereira SS, Lima DF, Oliveira JP, Fereira EL, Chaves MH, Almeida FR. Antinociceptive effect of Lecythis pisonis Camb. (Lecythidaceae) in models of acute pain in mice. J Ethnopharmacol. 2013;146(1):180–6.
31. Montrucchio DP, Córdova MM, Santos AR. Plant derived aporphinic alkaloid S-(-)-dicentrine induces antinociceptive effect in both acute and chronic inflammatory pain models: evidence for a role of TRPA1 channels. PLoS One. 2013;8(7):e67730.
32. Brandão MS, Pereira SS, Lima DF, Oliveira JP, Fereira EL, Chaves MH, Almeida FR. Antinociceptive effect of Lecythis pisonis Camb. (Lecythidaceae) in models of acute pain in mice. J Ethnopharmacol. 2013;146(1):180–6.
33. Montrucchio DP, Córdova MM, Santos AR. Plant derived aporphinic alkaloid S-(-)-dicentrine induces antinociceptive effect in both acute and chronic inflammatory pain models: evidence for a role of TRPA1 channels. PLoS One. 2013;8(7):e67730.
34. Hutchinson MR, Shavit Y, Grace PM, Rice KC, Maier SF, Watkins LR. Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol Rev. 2011;63(2):69–79.
35. Hutchinson MR, Shavit Y, Grace PM, Rice KC, Maier SF, Watkins LR. Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol Rev. 2011;63(2):69–79.
36. Sykes KT, White SR, Hurley RW, Mizoguchi H, Tseng LF, Hammond DL. Mechanisms responsible for the enhanced antinociceptive effects of micro-opioid receptor agonists in the rostral ventromedial medulla of male rats with persistent inflammatory pain. J Pharmacol Exp Ther. 2007;322(2):813–21.
37. Mahmud A, Santha P, Paule CC, Nagy I. Cannabinoid 1 receptor activation inhibits transient receptor potential vanilloid type 1 receptor-mediated cationic influx into rat cultured primary sensory neurons. Neuroscience. 2009;162(4):1202–11.
38. Ma W, Zhang Y, Bantel C, Eisenach JC. Medium and large injured dorsal root ganglion cells increase TRPV-1, accompanied by increased α2C-adrenoceptor co-expression and functional inhibition by clonidine. Pain. 2005;113(3):386–94.
39. Santha P, Jenes Á, Somogyi C, Nagy I. The endogenous cannabinoid anandamide inhibits transient receptor potential vanilloid type 1 receptor-mediated currents in rat cultured primary sensory neurons. Acta Physiol Hung. 2010;97(4):544–51.
40. Shapovalov G, Gikas D, Devillers M, Kondratskyi A, Gordienko D, Busserolles J, Bokhobza A, Eschalter A, Skryma R, Prevarskaya N. Opiates modulate thermosensation by internalizing cold receptor TRPM8. Cell Rep. 2013;4(3):504–15.
41. Wang C, Liu C, Wan H, Wang D, Sun D, Xu T, Yang Y, Qu Y, Xu Y, Jing X, Liu J, Chen S, Liu Z, Lin N. Wu-Tou Decoction Inhibits Chronic Inflammatory Pain in Mice: Participation of TRPV1 and TRPA1 Ion Channels. Biomed Res Int 2015;e328707.
42. Ji R, Berta T, Nederaaard M. Gila and pain: is chronic pain a gliopathy? Pain. 2013;154(01):510–28.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit